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Abstract: Redox imbalance is an adverse on-going phenomenon in renal transplant recipients (RTR).
Vitamin E has important antioxidant properties that counterbalance its deleterious effects. However,
plasma vitamin E affinity with lipids challenges interpretation of its levels. To test the hypothesis
that erythrocyte membranes represent a lipids-independent specimen to estimate vitamin E status,
we performed a cross-sectional study in a cohort of adult RTR (n = 113) recruited in a university
setting (2015–2018). We compared crude and total lipids-standardized linear regression-derived
coefficients of plasma and erythrocyte tocopherol species in relation to clinical and laboratory
parameters. Strongly positive associations of fasting lipids with plasma tocopherol became inverse,
rather than absent, in total lipids-standardized analyses, indicating potential overadjustment. Whilst,
no variables from the lipids domain were associated with the tocopherol species measured from
erythrocyte specimens. In relation to inflammatory status and clinical parameters with antioxidant
activity, we found associations in directions that are consistent with either beneficial or adverse effects
concerning α- or γ-tocopherol, respectively. In conclusion, erythrocytes offer a lipids-independent
alternative to estimate vitamin E status and investigate its relationship with parameters over other
biological domains. In RTR, α- and γ-tocopherol may serve as biomarkers of relatively lower or
higher vulnerability to oxidative stress and inflammation, noticeably in opposite directions.
Keywords: vitamin E; α-tocopherol; γ-tocopherol; erythrocyte; inflammation; oxidative stress;
cardiovascular disease; renal transplantation; renal transplant recipients
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1. Introduction
Oxidative stress (OS) occurs when there is an imbalance between the generation of reactive
oxygen species (ROS) and the antioxidant defense systems in the body, so that the latter becomes
overwhelmed. It constitutes a unifying mechanism of injury of many types of disease processes, and
it is causally involved in the pathogenesis of cardiovascular disease and malignancies by damaging
biomolecules, such as lipids, proteins, and DNA. Of note, in stable renal transplant recipients (RTR),
upon end-stage renal disease-related OS, elevated circulating metabolic by-products, maintenance of
immunosuppressive therapy, chronic allograft rejection, new-onset diabetes after transplantation, and
endothelial dysfunction are continuous and meaningful sources of ROS [1]. The role of free radicals
and antioxidants in cardiovascular—particularly in atherogenesis—as well as in malignancy diseases
is of encompassing relevance in the post-renal transplant setting, as both these conditions have been
shown to currently dispute the leading individual causes of death in stable RTR [2–4], thus ultimately
challenging efforts to improve long-term outcomes following renal transplantation [5].
Vitamin E is a lipid-soluble, chain-breaking type of antioxidant present in human blood. It
has the potential to influence a broad range of mechanisms underlying human health and disease.
Vitamin E works as a free radical scavenger and has the primary function of destroying peroxyl
radicals. Thus, it protects long-chain polyunsaturated fatty acids (e.g., cell membranes or low-density
lipoprotein cholesterol) from oxidation or destruction [6]. Its association with vitamin C is of great
pathophysiological importance, because inhibition of lipid peroxidation byα-tocopherol occurs through
its conversion into an oxidized α-tocopheroxyl radical, which in turn is regenerated to α-tocopherol
through reduction by redox-active reagents, in particular vitamin C [7–9]. It is established that
vitamin C and α-tocopherol interact as a network to protect lipids, proteins, and membranes from
oxidative damage, wherein this interaction not only involves homogeneous solutions but also liposomal
membrane systems, where vitamins C and E separately reside outside and within the membranes,
respectively, with vitamin C acting as a synergist that reduces oxidized vitamin E and enhances its
antioxidant activity, ultimately allowing for cooperative inhibition of oxidation [8,9]. This cooperative
inhibition of oxidation is a protective mechanism of pathophysiological relevance that ultimately
results in decreased formation of malondialdehyde [10].
α-tocopherol is the primary bioactive form of vitamin E, and is also best known for its role in
human health. Seven other naturally occurring vitamin E compounds have been described: β-, γ-,
and δ-tocopherol and α-, β-, γ-, and δ-tocotrienols. Reports on total tocopherol concentrations, which
adjust for the bioavailability of the various forms, do not reflect the bioactivity of α-tocopherol, which is
now used as the standard for dietary sufficiency [11]. Next, γ-tocopherol may have important adverse
or beneficial effects; however, the overall health effects of γ-tocopherol have not been established.
One of the major problems hampering correct interpretation of the raw association
between concentrations of vitamin E and high cardiovascular-risk conditions is attached to its
lipoprotein-dependent circulating transportation. The affinity of vitamin E for circulating lipids results
in a highly positive correlation with both fasting cholesterol and triglycerides concentrations [12,13].
The need to estimate vitamin E status has largely been addressed in clinical studies through performing
analyses of the quotient of vitamin E over the sum of total cholesterol and fasting triglycerides,
hereby negating the possible introduction of error from double correction for variance shared by total
cholesterol and fasting triglycerides. The current study was conducted to test the hypothesis that
erythrocyte vitamin E measurement may offer a lipids-independent specimen to estimate vitamin E
status, and thus endeavor a more representative assessment of its associations with parameters over
other biological domains. We aimed to compare coefficient estimates of the association of crude and
total lipids-standardized plasma and erythrocyte vitamin E species with inflammatory status and
clinical parameters with antioxidant activity in RTR, being a population of particularly high risk of
cardiovascular and malignancy disease.
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2. Materials and Methods
2.1. Study Design and Population
For this study, we used preliminary data from the TransplantLines Prospective Cohort Study and
Biobank of Solid Organ Transplant Recipients. In this ongoing study with a target follow-up duration
of 30 years, from June 2015, all solid organ transplantation patients of the University Medical Center
Groningen (UMCG, The Netherlands) were invited to participate. Exclusion criteria comprised no
mastery of the Dutch language or cognitive dysfunction. Renal transplant recipients with complete
plasma and erythrocyte vitamin E laboratory measurements were included in the analyses, resulting in
113 RTR, of whom the data is presented here. All patients provided signed written informed consent.
The study protocol was approved by the Institutional Review Board (METc 2014/077), adheres to
the UMCG Biobank Regulation, and is in accordance with the WMA Declaration of Helsinki and
the Declaration of Istanbul. The cohort study is registered at clinicaltrials.gov (TransplantLines: The
Transplantation Biobank, number NCT03272841). Full details on the rationale and study design are
reported [14].
2.2. Data Collection, and Clinical and Laboratory Measurements
Medical history and medication use, including immunosuppressive therapy, were extracted from
electronic hospital records. The measurement of clinical parameters has been described in detail [14].
Information about smoking status was collected from the self-administered Smoking Behaviour
Questionnaire. Serum creatinine values were used to obtain the estimated glomerular filtration rate
(eGFR) with the Chronic Kidney Disease Epidemiology Collaboration equation [15]. Blood was drawn
in the morning after an 8 to 12-h overnight fasting period. Participants were instructed to collect a
24-h urine sample according to strict protocol on the day before their visit to the outpatient clinic;
that is, discard their morning urine specimen, collect all subsequent urine throughout the next 24 h,
and include the next morning’s first specimen of the day of the visit to the outpatient clinic. Blood
drawing and receipt of the collected 24-h urine samples were performed by experienced nurses at
our outpatient clinic. Serum levels of total cholesterol, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, and total triglycerides were quantified with validated
routine enzymatic assays with spectrophotometric detection, all on a Roche Modular P chemistry
analyzer (Roche, Basel, Switzerland). On the same analyzer, fasting blood glucose was measured
via the hexokinase method. Serum uric acid and creatinine were measured via an enzymatic assay
with colorimetric detection on a Roche Modular P chemistry analyzer (Roche, Basel, Switzerland).
High-sensitivity C-reactive protein (hs-CRP) was determined by nephelometry (BN II system Siemens,
Marburg, Germany). HbA1C (glycated hemoglobin) was determined in ethylenediaminetetraacetic
acid (EDTA)-anticoagulated whole blood.
2.2.1. Vitamin E in Plasma
Whole blood was collected in tubes containing Na2EDTA as anticoagulant and shielded from
light. Plasma was collected after centrifugation and frozen at −20 ◦C until use. Analytes were extracted
by supported liquid extraction, eluted in 5% isopropanol in heptane and evaporated under nitrogen
flow, and resuspended in 250 µL of ethanol. Next, α-tocopherol and γ-tocopherol were separated by
liquid chromatography using a Luna Phenyl-Hexyl column (Phenomenex, Utrecht, The Netherlands).
Solvents used were 2 mM ammonium acetate dissolved in water with an 0.1% addition of formic
acid and 10 mM ammonium acetate dissolved in ethanol/methanol mixture with a 0.1% addition of
formic acid. Separation was followed by detection using a triple quad MS/MS system using deuterated
internal standards [α-tocopherol-d6 (IsoSciences, Ambler, AK, USA) and γ-tocopherol-d4 (Toronto
Research Chemicals Inc, North York, ON, Canada)].
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2.2.2. Vitamin E in Erythrocytes
Whole blood was collected in tubes containing Na2EDTA as anticoagulant and shielded from light.
After centrifugation, erythrocytes were washed three times in PBS and resuspended to a haematocrit
value of approximately 50%. In total, 500 µL of the suspension were mixed with an antioxidant mixture
(0.4% pyrogallol, 0.05% butylated hydroxytoluene in methanol, and 2.5% ascorbic acid in EDTA buffer
pH 5.4) and frozen at −20 ◦C until use. Erythrocyte cell counting was performed in the remaining
suspension using a Sysmex XN-9000 module (Sysmex, Etten-Leur, The Netherlands). Samples were
extracted using hexane, dried under nitrogen flow, and resuspended in 300 µL of ethanol. α-Tocopherol
and γ-tocopherol were separated by liquid chromatography using a Symmetry C18 column (Waters
Chromatography, Etten-Leur, The Netherlands) using a gradient of 0.01 M ammonium acetate, 40%
water, 60% acetonitrile, 25% dichloromethane, 37.5% acetonitril, and 37.5% methanol. Separation was
followed by detection at 292 nm using UV/VIS-spectroscopy using rac-Tocol (Abcam, Cambridge, UK)
as an internal standard.
2.3. Statistical Analyses
All analyses were performed using IBM SPSS Statistics, version 23.0 for Windows software (IBM,
Armonk, NY, USA). Data are expressed as mean ± standard deviation (SD) for normally distributed
variables, and as median (IQR) for skewed variables. Categorical data are expressed as n (percentage).
Age and sex-adjusted linear regression analyses were performed to examine the association of clinical
and laboratory parameters with vitamin E species (i.e., α- and γ-tocopherol). Residuals were checked
for normality and a natural log-transformation was applied when appropriate. For these analyses,
crude and total lipids-standardized concentrations of vitamin E species measured in plasma and
erythrocyte specimens were evaluated. Total lipids standardization was performed by calculating
the quotient of vitamin E species over total lipids (i.e., sum of total cholesterol and triglycerides). All
reported probability values are two-tailed, and a p ≤ 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristics
We included 113 RTR with a median age of 55 ± 14 years, 60% males, and 76% Caucasian. Plasma
and erythrocyte α-tocopherol concentrations were 1.4 ± 0.3 mg/dL and 0.27 ± 0.07 mg/1013 erythrocytes,
respectively. Plasma α-tocopherol (mg/dL)/total lipids (g/dL) ratio was 4.2 ± 0.7. None of the study
subjects were vitamin E deficient according to Horwitt et al. [16]. Plasma and erythrocyte γ-tocopherol
concentrations were 0.07 ± 0.03 mg/dL and 0.02 ± 0.01 mg/1013 erythrocytes, respectively. We first
investigated the associations of plasma and erythrocytes α- and γ-tocopherol with each other and with
fasting lipids. We found positive associations between plasma α- and γ-tocopherol (std. β = 0.36;
p < 0.001), as well as between erythrocytes α- and γ-tocopherol (std. β = 0.27; p = 0.01). Among
different models used to study the association between α-tocopherol with fasting lipids as its potential
independent determinants, we found that total lipids could explain 60% of the variation in plasma
α-tocopherol, whereas it could explain <1% of the variation in erythrocyte α-tocopherol (Table 1,
Model 4; Figure 1A,B). Following a similar pattern, although in a relatively smaller-scale, we found
that total lipids could explain 18% of the variation in plasma γ-tocopherol, whereas it could explain
<1% of the variation in erythrocyte γ-tocopherol (Table 2, Model 4, Figure 2A,B). Other combinations
of lipids (Tables 1 and 2; models 1–3, and 5–7) did not perform much better or worse than total lipids.
3.2. Plasma and Erythrocyte α-Tocopherol, and Biological Parameters
Linear regression analyses of age- and sex-adjusted associations between plasma and erythrocyte
α-tocopherol and demographics, anthropometrics, allograft function, transplant-related, and laboratory
parameters from the lipids, oxidative stress, and inflammatory biological domains are shown in Table 3.
Otherwise, strongly positive associations of crude plasmaα-tocopherol with fasting lipids were found to
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be significantly inverse, rather than absent, in total lipids-standardized plasma α-tocopherol analyses.
On the other hand, no variables from the lipids domain were associated with crude erythrocyte
α-tocopherol; whereas total lipids-standardized erythrocyte α-tocopherol was found to inversely
and strongly associate with parameters over the lipids domain. Distinctive results were found upon
analyses of the anti-oxidative agent high-density lipoprotein (HDL)-cholesterol. Whereas crude plasma
α-tocopherol was not associated with HDL-cholesterol, total lipids-standardized plasma α-tocopherol,
as well as crude erythrocyte α-tocopherol concentrations, were found to positively associate with
HDL-cholesterol (Table 1, under the subheading Antioxidants, pro-oxidants, and inflammation). Although,
both in plasma and erythrocyte specimens, we found an inverse association between uric and
total-lipids standardized α-tocopherol, this finding did not remain over non-standardized analyses of
erythrocyteα-tocopherol. Noteworthy, the anti-inflammatory and redox-active agent vitamin C directly
associated with total lipids-standardized plasma and erythrocyte α-tocopherol. This association was
consistent over non-standardized analyses of erythrocyte α-tocopherol. Finally, either in plasma or
erythrocyte specimens, an inverse association between glucose and α-tocopherol was found, but this
association was not consistent in non-standardized analyses of erythrocyte α-tocopherol, indicating
potential overadjustment.
3.3. Plasma and Erythrocyte γ-Tocopherol, and Biological Parameters
Linear regression analyses of age- and sex-adjusted associations between plasma and erythrocyte
γ-tocopherol and demographics, anthropometrics, allograft function, transplant-related, and laboratory
parameters from the lipids, oxidative stress, and inflammatory biological domains are shown in
Table 4. Analogous to α-tocopherol analyses, otherwise, strongly positive associations of crude
plasma γ-tocopherol with fasting lipids were found to be significantly inverse, rather than absent,
in total lipids-standardized plasma and erythrocyte γ-tocopherol analyses, whereas no significant
associations were observed in crude analyses of the γ-tocopherol concentrations measured from
erythrocyte specimens. Noteworthy, the inflammatory biomarker hs-CRP was directly associated with
total lipids-standardized plasma and erythrocyte γ-tocopherol. This association was consistent over
non-standardized analyses of erythrocyte γ-tocopherol.
Table 1. Association between plasma and erythrocytes α-tocopherol and fasting lipids in renal
transplant recipients (n = 113).
Plasma α-tocopherol Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Total cholesterol 0.68 *** — 0.53 *** — 0.49 *** — —
HDL cholesterol — — — — 0.10 0.29 *** 0.32 ***
Non-HDL cholesterol — — — — — — 0.49 ***
LDL cholesterol — — — — — 0.41 *** —
Triglycerides — 0.61 *** 0.43 *** — 0.48 *** 0.59 *** 0.48 ***
Total lipids — — — 0.77 *** — — —
R2 0.46 0.37 0.62 0.60 0.63 0.60 0.63
Erythrocytes α-tocopherol Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Total cholesterol 0.08 — 0.15 — 0.06 — —
HDL cholesterol — — — — 0.21 0.24 * 0.24 *
Non-HDL cholesterol — — — — — — 0.06
LDL cholesterol — — — — — 0.05 —
Triglycerides — −0.17 −0.22 * — −0.13 −0.11 −0.13
Total lipids — — — −0.08 — — —
R2 0.01 0.03 0.05 0.01 0.08 0.08 0.08
Associations between α-tocopherol and lipids were tested via univariable and multivariable linear regression
analyses of which standardized β coefficients are presented (* p < 0.05, *** p < 0.001).
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Table 2. Association between plasma and erythrocytesγ-tocopherol and fasting lipids in renal transplant
recipients (n = 113).
Plasma γ-tocopherol Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Total cholesterol 0.20 * — 0.08 — 0.10 — —
HDL cholesterol — — — — –0.05 –0.01 <0.001
Non-HDL cholesterol — — — — — — 0.10
LDL cholesterol — — — — — 0.05 —
Triglycerides — 0.39 0.37 *** — 0.35 ** 0.38 *** 0.35 **
Total lipids — — — 0.42 *** — — —
R2 0.04 0.16 0.16 0.18 0.16 0.16 0.16
Erythrocytes γ-tocopherol Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Total cholesterol 0.06 — 0.05 — 0.09 — —
HDL cholesterol — — — — –0.10 –0.07 –0.06
Non-HDL cholesterol — — — — — — 0.09
LDL cholesterol — — — — — 0.08 —
Triglycerides — 0.05 0.04 — −0.01 0.01 –0.01
Total lipids — — — 0.09 — — —
R2 0.004 0.003 0.01 0.01 0.01 0.01 0.01
Associations between γ-tocopherol and lipids were tested via univariable and multivariable linear regression
analyses of which standardized β coefficients are presented (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Table 3. Baseline characteristics of renal transplant recipients, and their associations with







None Lipids None Lipids
Plasma α-tocopherol, mg/dL, mean (SD) 1.4(0.3) — — — —
Quotient plasma α-tocopherol (mg/dL)/total
lipids (g/dL), mean (SD) 4.2(0.7) — — — —
Erythrocyte α-tocopherol, mg/1013 erythrocytes,
mean (SD) a
0.27(0.07) — — — —
Quotient erythrocyte α-tocopherol
(mg/1013 erythrocytes)/total lipids (g/dL), median
(IQR) a
0.79(0.61–1.04) — — — —
Demographics and anthropometrics
Age, years, mean (SD) † 55(14) 0.20 * 0.20 * 0.12 0.05
Gender, male, n (%) † 68(60) 0.15 0.19 * 0.13 0.08
Ethnicity, Caucasian, n (%) b 86(76) −0.13 0.13 0.10 0.19
Body mass index, kg/m2, median (IQR) c 25.9(24.2–29.3) 0.04 −0.17 −0.10 −0.17
Systolic blood pressure, mmHg, mean (SD) c 140(19) 0.06 0.04 0.003 −0.01
Diastolic blood pressure, mmHg, mean (SD) c 81(15) 0.002 −0.06 −0.17 −0.13
Diabetes mellitus, n (%) d 31(27) 0.01 −0.04 0.08 −0.01
Current smoker, n (%) e 5(4) −0.04 0.01 −0.01 0.02
Allograft function and transplantation
Creatinine, mg/dL, mean (SD) 1.5(0.4) 0.09 −0.04 0.01 −0.05
eGFR, mL/min/1.73 m2, mean (SD) 51(16) −0.11 0.001 −0.08 0.01
Dialysis vintage d
<1 year, n (%) 62(56) — — — —
1–5 years, n (%) 37(33) −0.13 −0.13 −0.16 −0.06
>5 years, n (%) 11(10) 0.17 0.06 0.01 −0.06
Time since transplantation, years, median (IQR) f 1(1–10) 0.20* 0.07 0.02 −0.08
Lipids
Total cholesterol, mg/dL, mean (SD) 181(38) 0.66 *** −0.14 0.06 −0.46 ***
Non-HDL cholesterol, mg/dL, mean (SD) 127(37) 0.67 *** −0.24 ** −0.03 −0.54 ***
LDL cholesterol, mg/dL, mean (SD) 110(35) 0.57 *** −0.13 0.01 −0.41 ***
Triglycerides, mg/dL, median (IQR) 151(101–197) 0.61 *** −0.59 *** −0.17 −0.74 ***
Total lipid, mg/dL, median (IQR) 334(272–397) 0.76 *** −0.51 *** −0.08 −0.76 ***
Antioxidants, pro-oxidants, and inflammation
HDL cholesterol, mg/dL, median (IQR) 50(41–64) −0.01 0.25 * 0.24* 0.21
γ-Glutamyltransferase, U/L, median (IQR) 30(19–42) 0.05 −0.05 −0.06 −0.10
Uric acid, mg/dL, mean (SD) 6.4(1.6) 0.20 −0.26 ** −0.18 −0.35 ***
Vitamin C, mg/dL, median (IQR) g 0.7(0.4–0.9) 0.10 0.22 * 0.23* 0.23 *
hs-CRP, mg/L, median (IQR) h 3.0(1.3–7.0) −0.11 0.09 −0.08 0.06
Glucose homeostasis
Glucose, mg/dL, median (IQR) 99(90–114) 0.13 −0.21 * −0.04 −0.31 *
HbA1C, %, median (IQR) 5.8(5.4–6.5) 0.09 0.09 0.02 −0.03
Associations between baseline characteristics and plasma and erythrocyte α-tocopherol concentration were tested
via multivariable age- and sex-adjusted linear regression analyses, of which standardized β coefficients are presented
(* p < 0.05, ** p < 0.01, and *** p < 0.001). Data available in a 111, b 90, c 112, d 110, e 55, f 109, g 99, and h 105 patients.
† Associations were adjusted for age or gender, where applicable. Abbreviations: hs-CRP, high-sensitivity C-reactive
protein; eGFR, estimated glomerular filtration rate.
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Table 4. Baseline characteristics of renal transplant recipients, and their associations with







None Lipids None Lipids
Plasma γ-tocopherol, mg/dL, mean (SD) a 0.07(0.03) — — — —
Quotient plasma γ-tocopherol (mg/dL)/total lipids (g/dL), mean
(SD) a 0.22(0.08) — — — —
Erythrocyte α-tocopherol, mg/1013 erythrocyte, median (IQR) b 0.02(0.01) — — — —
Quotient erythrocyte α-tocopherol
(mg/1013 erythrocyte)/total lipids (g/dL), median (IQR) b 0.06(0.03) — — — —
Demographics and anthropometrics
Age, years, mean (SD) † 55(14) −0.10 −0.09 −0.14 −0.16
Gender, male, n (%) † 68(60) 0.13 0.10 0.08 0.06
Ethnicity, Caucasian, n (%) c 86(76) −0.03 0.16 0.16 0.27
Body mass index, kg/m2, median (IQR) a 25.9(24.2–29.3) 0.29 ** 0.16 0.07 −0.07
Systolic blood pressure, mmHg, mean (SD) a 140(19) −0.09 −0.11 −0.12 −0.12
Diastolic blood pressure, mmHg, mean (SD) a 81(15) 0.11 0.03 −0.09 −0.14
Diabetes mellitus, n (%) d 31(27) 0.17 0.09 0.11 0.04
Current smoker, n (%) e 5(4) 0.05 0.13 0.10 0.09
Allograft function and transplantation
Creatinine, mg/dL, mean (SD) 1.5(0.4) –0.05 –0.17 –0.05 –0.40
eGFR, mL/min/1.73 m2, mean (SD) 51(16) 0.07 0.18 0.03 0.08
Dialysis vintage d
<1 year, n (%) 62(56) — — — —
1–5 years, n (%) 37(33) 0.10 0.12 0.002 0.03
>5 years, n (%) 11(10) −0.10 −0.15 −0.02 −0.07
Time since transplantation, years, median (IQR) b 1(1–10) 0.08 −0.02 0.02 −0.04
Lipids
Total cholesterol, mg/dL, mean (SD) 181(38) 0.19 * −0.23 * 0.07 −0.29 **
Non-HDL cholesterol, mg/dL, mean (SD) 127(37) 0.28 ** −0.21 * 0.12 −0.29 **
LDL cholesterol, mg/dL, mean (SD) 110(35) 0.16 −0.21 * 0.10 −0.21 *
Triglycerides, mg/dL, median (IQR) 151(101–197) 0.40 *** −0.22 * 0.06 −0.44 ***
Total lipid, mg/dL, median (IQR) 334(272–397) 0.42 *** −0.2 5** 0.10 −0.45 ***
Antioxidants, pro-oxidants, and inflammation
HDL cholesterol, mg/dL, median (IQR) 50(41–64) −0.20 * −0.07 −0.12 −0.02
γ-Glutamyltransferase, U/L, median (IQR) 30(19–42) 0.05 −0.003 −0.03 −0.03
Uric acid, mg/dL, mean (SD) 6.4(1.6) 0.10 −0.16 −0.04 −0.18
Vitamin C, mg/dL, median (IQR) f 0.7(0.4–0.9) −0.17 −0.05 0.03 0.12
hs-CRP, mg/L, median (IQR) g 3.0(1.3–7.0) 0.14 0.23 * 0.24 * 0.20 *
Glucose homeostasis
Glucose, mg/dL, median (IQR) 99(90–114) 0.21 * 0.01 0.13 −0.05
HbA1C, %, median (IQR) 5.8(5.4–6.5) 0.11 0.07 −0.001 −0.04
Associations between baseline characteristics and plasma and erythrocyte γ-tocopherol concentration were tested
via multivariable age- and sex-adjusted linear regression analyses, of which standardized β coefficients are presented
(* p <0.05, ** p <0.01, and *** p <0.001). Data available in a 112, b 109, c 90, d 110, e 55, f 99 and g 105 patients.
† Associations were adjusted for age or gender, where applicable. Abbreviations: hs-CRP, high-sensitivity C-reactive
protein; eGFR, estimated glomerular filtration rate.
4. Discussion
In the current cohort study of RTR, we found that total lipids (i.e., total cholesterol plus triglycerides)
significantly explained 60% and 18% of the variation in plasma α- and γ-tocopherol, whereas they only
explained <1% of the variation in α- and γ-tocopherol measured from erythrocryte specimens. As for
the association of plasma α- and γ-tocopherol species with fasting lipids, we consistently found an
inversion of standardized regression coefficients from positive to negative values in lipids-standardized
analyses, indicating potential overadjustment. In turn, otherwise, absent associations of erythrocyte
α- and γ-tocopherol concentrations with parameters over the lipids domain consistently became
inverse in total lipids-standardized analyses, which may likewise be indicative of overcorrection.
These findings leave the conclusion that vitamin E species measured from erythrocytes may offer a
lipids-independent specimen to estimate vitamin E status, and thus endeavor a more representative
assessment to investigate its association with parameters over other biological domains.
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Within the lipids domain, HDL cholesterol contributes to total cholesterol and thus it may
likely be expected to positively correlate with total cholesterol. However, because of the action of
circulating cholesterol ester transfer protein, it may be anticipated to inversely correlate with fasting
triglycerides [17]. Moreover, because of its antioxidant activity [18–20], one would foresee a positive
association of HDL cholesterol with vitamin E. Indeed, in agreement with the rather outlier pattern
expected for HDL cholesterol in comparison to other lipid parameters, we found it to positively associate
with total lipids-standardized plasma α-tocopherol, with a consistent pattern over non-standardized
analyses with erythrocyte α-tocopherol. Interestingly, this pattern is similar to that observed for
the radical scavenger type of antioxidant, vitamin C. These findings are particularly relevant in the
post-kidney transplantation setting, as we have previously shown that both HDL cholesterol eﬄux and
vitamin C status are associated with long-term kidney graft and patient survival, respectively [21,22].
We found the associations between α-tocopherol and γ-tocopherol concentrations to be positive,
in both analyses specimens. Whilst, interestingly, the physiological regulatory direction of associations
of γ-tocopherol with biological variables, if present, were opposite to those observed for α-tocopherol.
α-tocopherol directly associated with HDL-cholesterol and vitamin C, and inversely with uric acid.
On the other hand, irrespective of standardization methods, γ-tocopherol directly associated with
hs-CRP. Previous studies have reported contrapositive associations of α- and γ-tocopherol with
parameters over different biological domains, particularly in relation to inflammation, oxidative stress,
and aging [23–29]. In agreement with our findings, these studies reported results in directions that
are consistent with beneficial effects concerning α-tocopherol, and adverse outcomes concerning
γ-tocopherol. Specific intracellular mechanisms for either anti- or pro-inflammatory functions of these
tocopherols species have been proposed by Cook-Mills et al. [30–32]. While recruitment of lymphocytes
and eosinophils is inhibited by α-tocopherol, it has been shown that γ-tocopherol elevates migration of
leukocytes through intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1)-dependent mechanisms at the endothelium level. Upon direct binding of protein kinase Cα
(PKCα), α- and γ-tocopherol, furthermore, have been shown to differentially regulate downstream
intracellular signaling of these molecules, which is the proposed mechanistic background to explain
the demonstrated contrapositive regulatory biological directions of these vitamin E isoforms [30–32].
Remarkably, these opposing regulatory functions of vitamin E isoforms may have considerable impact
on the interpretation of a broad number of clinical studies on vitamin E performed over the last decades,
which remains to be reviewed and critically analyzed.
The complexity of the antioxidants and pro-oxidants network is partly underscored by the action
of one antioxidant depending on the proper function of other members of the antioxidant system,
and to a considerable extent also articulated by physicochemical conditions of microenvironments in
biological fluids. Uric acid, despite being an endogenous antioxidant that accounts for about 70% of the
total antioxidant capacity of plasma [33], has largely been shown to associate and predict development
of hypertension, atherosclerosis, visceral obesity, insulin resistance, dyslipidemia, diabetes type II,
kidney disease, and cardiovascular events [34–41]. This paradox may rise from the duality of activities
displayed by uric acid in either hydrophilic or hydrophobic physicochemical microenvironments.
Considerations of uric acid regarding analyses at different compartments and at different levels of
biological organization point towards a contributory role of its pro-oxidative actions in common
pathogenic pathways leading to cardiovascular disease in chronic kidney disease patients. Thus, the
inverse association of plasma and erythrocytes α-tocopherol with uric acid in total-lipids standardized
analyses, which was not consistent over non-standardized analyses in erythrocytes, seems to be in
line with the proposed protective effects of α-tocopherol against potentially deleterious pro-oxidant
activity of uric acid, whilst they underline the relevance of accounting for lipophilic conditions in the
study of uric acid in relation to α-tocopherol and within the complex antioxidants network.
To our knowledge, the current study is the first study to investigate circulating levels of α- and
γ-tocopherol species measured in plasma, as well as in erythrocyte specimens. The latter may allow a
total lipids-independent vitamin E status estimation to investigate its relation to inflammatory status
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and clinical parameters with antioxidant activity in RTR. This is relevant because RTR are a population
at particular vulnerability to oxidative damage on the basis that cardiovascular and malignancy disease
are major hazards in the post-renal transplantation setting [2–5]. It should be acknowledged that
we did not have access to data on urinary metabolites of vitamin E species, which could have given
us further information on system vitamin E status [42]. Next, our study is cross-sectional in nature,
which precludes us from drawing hard conclusions about cause-and-effect relations. Whereas we
evaluated routinely measured clinical parameters with established antioxidant activity, the association
with markers of oxidative damage remains to be further studied. Upon these preliminary results,
nonetheless, forthcoming analyses of the data to be generated by the long-lasting TransplantLines
Prospective Cohort Study and Biobank of Solid Organ Transplant Recipients [14] are warranted, in
order to longitudinally relate vitamin E status, evaluated by means of α- and γ-tocopherol measured
in erythrocytes membranes, to inflammatory state and oxidative stress by means of total antioxidant
capacity of plasma and lipid peroxidation biomarkers, and to assess its association to hard long-term
outcomes (e.g., overall and cause-specific graft and recipient loss), and to be able to likewise account
for liver, lung, and heart transplant recipients.
5. Conclusions
In conclusion, erythrocytes offer a lipids-independent alternative to estimate vitamin E status
and investigate its relationship with parameters over other biological domains. Despite a positive
association between α- and γ-tocopherol themselves in both analyzed specimens (i.e., plasma and
erythrocytes), we found intriguing opposing associations of α- and γ-tocopherol in the biological
domains of inflammation and redox imbalance. The current findings support the notion that, in
opposite regulatory biological directions, α- and γ-tocopherol, respectively, have the characteristics of
biomarkers associated with a relatively lower and higher vulnerability to these long-term ongoing
pathogenic phenomena in RTR. Further studies are warranted to evaluate whether considerate
supplementation of vitamin E species may represent a not yet appropriately recognized opportunity to
decrease the burden by long-term low-grade inflammation and persistent oxidative challenge, and its
deleterious consequences in RTR.
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